V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20106400 | 20169699 | 1.6 | 59.2 | Palliative (P) | null | 2018-07-30 | EEF or EOF | N | N | NAB-PACLITAXEL | 100735055 |
| 20106458 | 20169700 | null | null | Palliative (P) | 2019-12-30 | 2020-01-28 | NAB PACLITAXEL | 01 | N | ATEZOLIZUMAB + BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101531659 |
| 20106829 | 20169701 | 1.72 | 89 | Neo-adjuvant (N) | 2018-04-18 | 2018-04-25 | TOPARP TRIAL | 02 | N | TCX | 100609154 |
| 20106930 | 20169702 | 1.82 | 81.8 | 03 | 2021-09-22 | 2021-10-03 | AFLIBERCEPT + FLUOROURACIL + IRINOTECAN | N | null | SOTORASIB | 101426233 |
| 20108324 | 20169703 | 1.6 | 99 | Palliative (P) | 2016-12-06 | 2016-12-07 | Capecitabine + Streptozocin | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100691809 |
| 20110317 | 20169704 | 1.77 | 48.4 | Disease modification (D) | 2021-04-29 | 2021-04-30 | TEMOZOLOMIDE | 02 | N | CAPECITABINE + CISPLATIN + MITOMYCIN | 101063964 |
| 20110422 | 20169705 | 1.61 | 106 | Adjuvant (A) | 2022-05-06 | 2022-05-16 | TEMOZOLOMIDE | 02 | N | TEYSUNO | 101057072 |
| 20111083 | 20169706 | 1.89 | 86.9 | null | 2017-10-28 | 2017-10-28 | CAPE + OXALIPLATIN + TRASTUZUMAB | N | N | BINIMETINIB + CETUXIMAB + ENCORAFENIB | 101287389 |
| 20111191 | 20169707 | 1.61 | 50.3 | null | 2018-06-06 | 2020-12-07 | Cabazitaxel | 02 | N | PALBOCICLIB | 100997276 |
| 20111387 | 20169708 | 1.82 | 46.8 | null | 2021-07-18 | 2021-07-19 | null | 02 | N | CISPLATIN + TEYSUNO | 101824299 |
| 20112076 | 20169709 | 1.81 | 59.7 | null | 2022-03-17 | 2022-04-15 | Pazopanib | 02 | N | MITOMYCIN | 101860498 |
| 20112298 | 20169710 | 1.81 | 44.1 | Palliative (P) | 2016-07-16 | 2016-07-21 | Bendamustine + Thalidomide +/- Dex | 02 | null | HEPATOBLASTOMA HR CARBO/DOX | 101600163 |
| 20112329 | 20169711 | 1.79 | 75.9 | Palliative (P) | 2021-04-01 | 2021-04-07 | Cape+Cetuximab+Oxalip (2 wk) Load | 02 | N | CISPLATIN + FLUOROURACIL + RT | 101540728 |
| 20112682 | 20169713 | 0 | 11 | Palliative (P) | 2020-04-25 | 2020-04-26 | PONATINIB | 02 | N | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 100909926 |
| 20112751 | 20169714 | 1.65 | 10.1 | Palliative (P) | 2022-01-13 | 2022-01-14 | CISPLATIN + FLUOROURACIL + RT | 02 | N | IRINOTECAN + MDG + PANITUMUMAB | 101260811 |
| 20112881 | 20169715 | 1.48 | null | Palliative (P) | 2022-04-22 | 2022-05-05 | ACTICCA-1 Trial | 1 | N | CAPECITABINE + STREPTOZOCIN | 101400442 |
| 20113008 | 20169716 | 1.57 | 67.2 | Palliative (P) | null | 2021-10-29 | CAP + RT | N | null | BEVACIZUMAB + CAPE + IRINOTECAN | 100159269 |
| 20113281 | 20169718 | 1.7 | 77 | Palliative (P) | 2020-07-02 | 2020-07-09 | Carboplatin + Raltitrexed | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101332264 |
| 20113533 | 20169719 | 1.7 | 76.7 | Palliative (P) | null | 2020-01-11 | IPM | 02 | null | LOMUSTINE | 100225808 |
| 20114769 | 20169720 | 1.81 | 59.55 | null | 2022-03-23 | 2022-03-24 | Bevacizumab + Oxaliplatin +MdG | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101262332 |
| 20115021 | 20169721 | 1.57 | 87.3 | Palliative (P) | 2022-05-04 | 2022-05-05 | MCX | 02 | null | TOPOTECAN | 100795971 |
| 20115341 | 20169722 | null | null | Palliative (P) | 2020-02-04 | 2020-02-05 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | null | IBRUTINIB | 101484039 |
| 20115685 | 20169723 | 1.82 | null | Palliative (P) | 2019-06-19 | 2019-06-21 | Capecitabine + Carboplatin + RT | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100099316 |
| 20116757 | 20169724 | 1.82 | 93.6 | Palliative (P) | 2022-04-16 | 2022-04-29 | CARBOPLATIN + GEMCITABINE | 02 | N | HEPATOBLASTOMA HR CARBO/DOX | 100521669 |
| 20117027 | 20169725 | 1.8 | 69.2 | null | null | 2018-10-15 | CISPLATIN + FLUOROURACIL + RT | N | N | SCOPE 1 TRIAL | 101790858 |
| 20117132 | 20169726 | 1.53 | 62.8 | Neo-adjuvant (N) | 2018-06-20 | 2018-07-17 | Doxorubicin + Olaratumab | null | N | NIRAPARIB | 101176873 |
| 20117638 | 20169728 | 1.72 | 66 | null | 2020-07-29 | 2020-07-29 | Bortezomib + MELPHALAN | 02 | null | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100909407 |
| 20117727 | 20169729 | 1.83 | 88 | null | 2020-12-26 | 2021-01-06 | CAPECITABINE + LOMUSTINE | 02 | null | AFATINIB | 100676526 |
| 20118980 | 20169730 | 1.77 | 92.2 | Palliative (P) | 2019-09-23 | 2020-04-25 | DARATUMUMAB | null | null | TRABECTEDIN | 100678225 |
| 20119269 | 20169731 | 1.55 | 118 | Palliative (P) | 2019-12-18 | 2019-12-20 | PERTUZUMAB + TRASTUZUMAB | 02 | N | ECARBOX | 100672395 |
| 20119819 | 20169732 | 1.53 | 81.9 | null | 2018-08-08 | 2018-08-18 | IBRUTINIB | 02 | N | BACILLUS CALMETTE-GUERIN | 100531834 |
| 20119905 | 20169733 | 1.52 | 97.7 | null | 2018-09-26 | 2018-09-26 | Doxorubicin 20mg/m2 7 day | 02 | null | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 101806113 |
| 20120501 | 20169735 | 1.84 | 70 | Adjuvant (A) | 2021-10-09 | 2021-10-11 | CISPLATIN + RT | 02 | null | MITOXANTRONE | 101597204 |
| 20120917 | 20169736 | 1.93 | 69.4 | Palliative (P) | 2016-03-28 | 2017-07-12 | EC | 02 | N | GO2 TRIAL | 101524385 |
| 20121101 | 20169737 | 1.64 | 64 | 03 | 2020-09-08 | 2020-09-28 | ECarboX | 02 | N | ACTICCA-1 TRIAL | 101185358 |
| 20121353 | 20169738 | 0.94 | 80.9 | Curative (C) | 2019-08-06 | 2019-08-30 | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL + Trastuzumab | 02 | N | GO2 TRIAL | 100378787 |
| 20121424 | 20169739 | 1.57 | 115.9 | null | 2019-12-24 | 2020-06-08 | SCOPE 2 TRIAL | 02 | N | BACILLUS CALMETTE-GUERIN | 100191559 |
| 20121595 | 20169740 | 1.57 | 49 | Curative (C) | 2018-09-10 | 2019-01-19 | Gemcitabine + RT pancreas | 2 | N | BORTEZOMIB | 100428743 |
| 20121799 | 20169741 | 1.54 | 68.2 | null | 2020-12-18 | 2021-01-09 | null | 02 | null | ECF | 101838727 |
| 20121827 | 20169742 | 1.77 | 61 | Palliative (P) | 2021-03-13 | 2021-04-21 | TOPARP TRIAL | 2 | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 101766179 |
| 20122070 | 20169743 | 1.8 | 19.9 | Curative (C) | 2018-04-01 | 2018-04-02 | Cabazitaxel | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101572607 |
| 20122584 | 20169745 | 1.71 | 70.6 | null | 2020-03-13 | 2020-04-10 | FCR Oral - Cycle 2 onwards | 02 | N | IRINOTECAN + MDG + PANITUMUMAB | 100795329 |
| 20122862 | 20169746 | 1.69 | 90.4 | null | 2019-07-19 | 2019-08-10 | Capecitabine+Cisplatin+Streptozocin | 02 | null | HYDROXYCARBAMIDE | 101168979 |
| 20122938 | 20169747 | 1.71 | 78 | Palliative (P) | 2021-08-31 | 2021-09-07 | MITOMYCIN | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100259335 |
| 20123140 | 20169748 | 1.51 | 48 | Palliative (P) | 2018-03-29 | 2019-04-17 | Cisplatin + Docetaxel +Fluorouracil | 02 | null | CAPECITABINE + CARBOPLATIN + RT | 101760433 |
| 20123468 | 20169749 | 1.84 | 77.5 | Palliative (P) | 2020-01-15 | 2020-01-30 | Docetaxel + nintedanib | 01 | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 100203840 |
| 20123916 | 20169751 | 1.65 | 58.8 | Neo-adjuvant (N) | 2016-11-29 | 2016-12-15 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | null | FLUOROURACIL + RT | 100148757 |
| 20124005 | 20169752 | 0 | 67.2 | Adjuvant (A) | 2020-11-18 | 2020-12-15 | MIC | 02 | null | DOCETAXEL + GEMCITABINE | 101570061 |
| 20124067 | 20169753 | 1.83 | 95 | Palliative (P) | 2018-11-05 | 2018-11-14 | PCV | 02 | N | IBRUTINIB | 100017932 |
| 20124087 | 20169754 | 1.55 | 57.75 | null | 2018-06-20 | 2018-06-26 | Ixazomib + Lenalidomide | 02 | Y | INTERAACT TRIAL | 100508317 |